3dmi Research Group, Department of Medical Physics, School of Medicine, University of Patras, Greece.
Institute of Science and Technology for Ceramics (ISTEC), National Research Council (CNR), Italy.
Mol Imaging. 2021 Jan 15;2021:6677847. doi: 10.1155/2021/6677847. eCollection 2021.
Molecular imaging holds great promise in the noninvasive monitoring of several diseases with nanoparticles (NPs) being considered an efficient imaging tool for cancer, central nervous system, and heart- or bone-related diseases and for disorders of the mononuclear phagocytic system (MPS). In the present study, we used an iron-based nanoformulation, already established as an MRI/SPECT probe, as well as to load different biomolecules, to investigate its potential for nuclear planar and tomographic imaging of several target tissues following its distribution via different administration routes. Iron-doped hydroxyapatite NPs (FeHA) were radiolabeled with the single photon -emitting imaging agent [Tc]TcMDP. Administration of the radioactive NPs was performed via the following four delivery methods: (1) standard intravenous (iv) tail vein, (2) iv retro-orbital injection, (3) intratracheal (it) instillation, and (4) intrarectal installation (pr). Real-time, live, fast dynamic screening studies were performed on a dedicated bench top, mouse-sized, planar SPECT system from = 0 to 1 hour postinjection (p.i.), and consequently, tomographic SPECT/CT imaging was performed, for up to 24 hours p.i. The administration routes that have been studied provide a wide range of possible target tissues, for various diseases. Studies can be optimized following this workflow, as it is possible to quickly assess more parameters in a small number of animals (injection route, dosage, and fasting conditions). Thus, such an imaging protocol combines the strengths of both dynamic planar and tomographic imaging, and by using iron-based NPs of high biocompatibility along with the appropriate administration route, a potential diagnostic or therapeutic effect could be attained.
分子成像在利用纳米粒子（NPs）无创监测多种疾病方面具有巨大的潜力，被认为是癌症、中枢神经系统以及心脏或骨骼相关疾病和单核吞噬细胞系统（MPS）疾病的有效成像工具。在本研究中，我们使用了一种铁基纳米制剂，该制剂已经作为 MRI/SPECT 探针建立，并且可以负载不同的生物分子，以研究其通过不同给药途径分布后对几种靶组织进行核平面和断层成像的潜力。铁掺杂羟基磷灰石 NPs（FeHA）被单光子发射成像剂 [Tc]TcMDP 放射性标记。放射性 NPs 的给药通过以下四种给药方法进行：（1）标准静脉（iv）尾静脉，（2）iv 眶后注射，（3）气管内（it）滴注，和（4）直肠内安装（pr）。在专用台式、小鼠大小的平面 SPECT 系统上，从注射后 0 到 1 小时（p.i.）进行实时、活体、快速动态筛选研究，随后进行断层 SPECT/CT 成像，直至 24 小时 p.i. 已经研究的给药途径为各种疾病提供了广泛的可能的靶组织。可以按照此工作流程优化研究，可以在少数动物（注射途径、剂量和禁食条件）中快速评估更多参数。因此，这种成像方案结合了动态平面和断层成像的优势，并且通过使用高生物相容性的铁基 NPs 和适当的给药途径，可以实现潜在的诊断或治疗效果。
